6 February 2024BiotechnologyMuireann Bolger

NanoString files for bankruptcy after costly 10x feud

Biotech claims action was necessary due to unfavourable rulings after being targeted by a rival | Accuses gene technology firm of attempting to shrink the competitive landscape for different spatial biology platforms.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

10x Genomics awarded $31m in key ruling over NanoString

21 November 2023 District court’s verdict found NanoString infringed on seven patents related to protein detection tech | Marks the third victory for 10x Genomics in the last six months | NanoString ‘must drop the charade’ says 10x CEO.

Biotechnology

NanoString to appeal 10x’s UPC injunction ‘immediately’

21 September 2023 The spatial biology firm will appeal the Unified Patent Court’s preliminary injunction | NanoString accuses 10x of ‘misusing non-final court rulings…to eliminate competition in the spatial transcriptomics market’.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

NanoString files for bankruptcy after costly 10x feud

More on this story

Editor's picks

Editor's picks

More features